Protective effect of acellular pertussis vaccines

Blennow, Margareta; Hedenskog, Staffan; Granström, Marta

doi:10.1007/bf01962341

Cited by 22 publications

(9 citation statements)

References 15 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five of 26 children >-4 years lacked detectable antibodies to pertussis toxin. Since there are reasons to believe that serum antibodies against pertussis toxin are important for protection [4][5][6][7][8], this study indicates that booster doses with vaccines containing pertussis toxoid are needed for life-long protection. In contrast to the decline in pertussis toxin antibodies with time, FHA antibodies remained high in older children.…”

Section: Discussionmentioning

confidence: 99%

“…In 1979 it was proposed that pertussis, like diphtheria and tetanus, is a toxin-mediated disease [1], and pertussis toxin was purified soon afterwards [2,3]. Inactivated pertussis toxin induces at least partial protection against pertussis [4][5][6], and the protection seems to be at least partly mediated through toxin neutralizing serum antibodies [7,8]. A surface protein of B. pertussis, filamentous hemagglutinin (FHA) might also contribute to protection against disease [9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serumantikörper gegen die Komponenten der Diphtherie-Tetanus-Pertussis-Vakzine bei polnischen Kindern in Beziehung zum Impfstatus

Torbicka

Lagergård²,

Trollfors³

1995

Infection

View full text Add to dashboard Cite

In Poland vaccination against diphtheria, tetanus and pertussis (DTP) is recommended from 2-3 months of age. Three doses at approximately 6-week intervals are given. A booster dose of DTP is given at 19-24 months and boosters of DT at 6 and 14 years. In this study serum samples were obtained from 166 Polish children aged 2 weeks to 14 years. Vaccination status was verified from the children's Health Books. Antibodies were determined against pertussis toxin, filamentous hemagglutinin (FHA), pertactin, tetanus toxoid and diphtheria toxin. Antibodies of maternal original against all five antigens were detected in almost all sera from infants not yet vaccinated. Antibody levels increased with the number of vaccinations given. Children who had recently received the fourth vaccination had the highest antibody levels. Antibody levels decreased with time after the fourth vaccination for all antibodies except FHA. It was concluded that the Polish whole cell pertussis vaccine stimulates antibodies against pertussis toxin, FHA and pertactin, but that antibodies against FHA probably also are stimulated by cross-reacting antigens. Diphtheria toxin and tetanus toxoid antibodies were above protective levels in all vaccinated children, but the long-term decreases justify the booster dose at 14 years. Twenty-five of 166 children (15%) had a vaccination status which deviated from recommendations demonstrating a need to increase the vaccination rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serumantikörper gegen die Komponenten der Diphtherie-Tetanus-Pertussis-Vakzine bei polnischen Kindern in Beziehung zum Impfstatus

Torbicka

Lagergård²,

Trollfors³

1995

Infection

View full text Add to dashboard Cite

show abstract

“…From mid-1982 to mid-1983, Blennow et al carried out a nonblinded but prospective cohort study involving 1,140 infants in Sweden (58). In this trial, 525 infants received three doses of a plain whole-cell vaccine (Pertussis Vaccine Wellcome; Wellcome) licensed in the United Kingdom and 615 unvaccinated infants served as controls.…”

Section: B Pertussis Vaccinesmentioning

confidence: 99%

Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due toBordetella pertussisand OtherBordetellaSubspecies

2005

View full text Add to dashboard Cite

Bordetella respiratory infections are common in people (B. pertussis) and in animals (B. bronchiseptica). During the last two decades, much has been learned about the virulence determinants, pathogenesis, and immunity of Bordetella. Clinically, the full spectrum of disease due to B. pertussis infection is now understood, and infections in adolescents and adults are recognized as the reservoir for cyclic outbreaks of disease. DTaP vaccines, which are less reactogenic than DTP vaccines, are now in general use in many developed countries, and it is expected that the expansion of their use to adolescents and adults will have a significant impact on reducing pertussis and perhaps decrease the circulation of B. pertussis. Future studies should seek to determine the cause of the unique cough which is associated with Bordetella respiratory infections. It is also hoped that data gathered from molecular Bordetella research will lead to a new generation of DTaP vaccines which provide greater efficacy than is provided by today's vaccines

show abstract

“…2,6 Open studies and a double-blind study indicate that pertussis toxoids induce protection. [7][8][9] The present trial was performed in Sweden, where pertussis has been endemic since the early 1970s, when changes in production made the Swedish-made whole-cell vaccine ineffective. 10 When the incidence of pertussis increased despite vaccination rates of about 90 percent, the recommended infant vaccine was withdrawn in 1979.…”

mentioning

confidence: 99%